ASH 2014 | ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 2)

Jia Ruan

Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the clinical relevance of a phase II study of the biologic doublet, lenalidomide plus rituximab, as initial treatment for mantle cell lymphoma.

Share this video